<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144740</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-041 - Part 2</org_study_id>
    <nct_id>NCT02144740</nct_id>
  </id_info>
  <brief_title>Effect of NWT-03 on Blood Pressure</brief_title>
  <official_title>A Study of Two Parts to Determine the Effect of NWT-03 on Blood Pressure in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newtricious R&amp;D BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newtricious R&amp;D BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 2 of the study will assess the effect of 2g of NWT-03 (an egg-white protein hydrolysate)&#xD;
      on systolic and diastolic blood pressure and flow-mediated dilation in a crossover designed&#xD;
      study in healthy adults with mild hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in daytime systolic blood pressure at 4 and 8 weeks</measure>
    <time_frame>For both intervention periods: 48h ABPM before baseline visit, 4 and 8 weeks after baseline visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daytime diastolic blood pressure at 4 and 8 weeks</measure>
    <time_frame>For both intervention periods: 48h ABPM before baseline visit, 4 and 8 weeks after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in flow-mediated dilation (only for n=10 subgroup) at 8 weeks</measure>
    <time_frame>Both periods: at baseline and after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 48 before baseline in albuminuria at 8 weeks</measure>
    <time_frame>For each period: 48h before baseline and 8 weeks after baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Vitals (weight, height, BMI)</measure>
    <time_frame>During screening (up to 4 weeks before baseline)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>eGFR</measure>
    <time_frame>Each period: 48h before baseline and week 8</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>NWT-03, then placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then NWT-03</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NWT-03, an egg-white protein hydrolysate</intervention_name>
    <description>For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given</description>
    <arm_group_label>NWT-03, then placebo</arm_group_label>
    <arm_group_label>Placebo, then NWT-03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.</description>
    <arm_group_label>NWT-03, then placebo</arm_group_label>
    <arm_group_label>Placebo, then NWT-03</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be able to give written informed consent,&#xD;
&#xD;
          -  Be between 35 and 75 years of age,&#xD;
&#xD;
          -  Be in generally good health as determined by the investigator,&#xD;
&#xD;
          -  Smokers and non-smokers are eligible,&#xD;
&#xD;
          -  Have a stable body weight (&lt; 5% change) over the past 3-months,&#xD;
&#xD;
          -  Have a Body Mass Index (BMI) between 25 and 35 kg/m2,&#xD;
&#xD;
          -  Be mild hypertensive (Systolic Blood Pressure 140-159 mmHg &amp; Diastolic Blood Pressure&#xD;
             80-99 mmHg).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study if they meet any of the below criteria;&#xD;
&#xD;
          1. Are less than 35 and greater than 75 years of age,&#xD;
&#xD;
          2. Females are pregnant, lactating or wish to become pregnant during the study. Female&#xD;
             subject is currently either of:&#xD;
&#xD;
               1. non-childbearing potential (i.e., physiologically incapable of becoming pregnant,&#xD;
                  including any female who is post-menopausal or any female who is surgically&#xD;
                  sterilized (via documented hysterectomy or bilateral tubal ligation). (For&#xD;
                  purposes of this study, postmenopausal is defined as one year without menses), OR&#xD;
&#xD;
               2. child bearing potential, the subject is eligible to enter and participate in this&#xD;
                  study if she is not lactating and has a negative urine pregnancy test at the&#xD;
                  screening visit, visit 2 and upon completion of the study at visit 7. The subject&#xD;
                  must also agree to one of the following methods of contraception:&#xD;
&#xD;
                    -  Complete abstinence from intercourse two weeks prior to administration of&#xD;
                       study drug, throughout the clinical trial, until the completion of follow-up&#xD;
                       procedures or for two weeks following discontinuation of the study&#xD;
                       medication in cases where subject discontinues the study prematurely.&#xD;
                       (Subjects utilizing this method must agree to use an alternate method of&#xD;
                       contraception if they should become sexually active and will be queried on&#xD;
                       whether they have been abstinent in the preceding 2 weeks when they present&#xD;
                       to the clinic for the Final Visit.) or,&#xD;
&#xD;
                    -  has a male sexual partner who is surgically sterilized prior to the Screen&#xD;
                       Visit and is the only male sexual partner for that subject or,&#xD;
&#xD;
                    -  sexual partner(s) is/are exclusively female or,&#xD;
&#xD;
                    -  Oral contraceptives (either combined or progestogen only) with&#xD;
                       double-barrier method of contraception consisting of spermicide with either&#xD;
                       condom or diaphragm. (Women of child-bearing potential using an oral&#xD;
                       contraceptive in combination with a double-barrier method of contraception&#xD;
                       are required to continue to use this form of contraception for 1 week&#xD;
                       following discontinuation of study medication).&#xD;
&#xD;
                    -  Use of double-barrier contraception, specifically, a spermicide plus a&#xD;
                       mechanical barrier (e.g. male condom, female diaphragm). The subject must be&#xD;
                       using this method for at least 1 week following the end of the study or,&#xD;
&#xD;
                    -  Use of any intrauterine device (IUD) with published data showing that the&#xD;
                       highest expected failure rate is less than 1% per year. The subject must&#xD;
                       have the device inserted at least 2 weeks prior to the first Screen Visit,&#xD;
                       throughout the study, and 2 weeks following the end of the study.&#xD;
&#xD;
          3. Are hypersensitive to any of the components of the test product,&#xD;
&#xD;
          4. Have a significant acute or chronic coexisting illness such as cardiovascular disease,&#xD;
             Chronic kidney disease (CKD), gastrointestinal disorder, endocrinological disorder,&#xD;
             immunological disorder, metabolic disease or any condition which contraindicates, in&#xD;
             the investigators judgement, entry to the study,&#xD;
&#xD;
          5. Having a condition or have taken a medication that the investigator believes would&#xD;
             interfere with the objectives of the study, pose a safety risk or confound the&#xD;
             interpretation of the study results; to include diuretics, blood pressure medication&#xD;
             and medication interfering with renin-angiotensin-aldosterone system (RAAS), such as&#xD;
             ACE-inhibitors, angiotensin receptor blockers, direct renin inhibitors or aldosterone&#xD;
             receptor inhibitor,&#xD;
&#xD;
          6. Are taking non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks of baseline&#xD;
             visit or for the duration of the trial,&#xD;
&#xD;
          7. Suffer from diabetes mellitus, either type I and type II,&#xD;
&#xD;
          8. Consume more than the recommended alcohol guidelines i.e. &gt;21 alcohol units/week for&#xD;
             males and &gt;14 units/week for females,&#xD;
&#xD;
          9. History of illicit drug use,&#xD;
&#xD;
         10. Use of nasal decongestants and other over-the counter or herbal preparation within 2&#xD;
             weeks of baseline visit and for the duration of the trial,&#xD;
&#xD;
         11. Heavy intake of coffee (i.e. more than 4 cups daily) within 2 weeks of baseline visit&#xD;
             and for the duration of the trial,&#xD;
&#xD;
         12. Individuals who, in the opinion of the investigator, are considered to be poor&#xD;
             attendees or unlikely for any reason to be able to comply with the trial,&#xD;
&#xD;
         13. Subjects may not be receiving treatment involving experimental drugs,&#xD;
&#xD;
         14. If the subject has been in a recent experimental trial, these must have been completed&#xD;
             not less than 60 days prior to this study. An exception will be made where subjects&#xD;
             have participated in part 1 of the study,&#xD;
&#xD;
         15. Have a malignant disease or any concomitant end-stage organ disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atlantia Food CRO</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flow-mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

